Clofazimine broadly inhibits coronaviruses including SARS-CoV-2Shuofeng Yuan, Kwok‐Yung Yuen, Xin Yin et al.|Nature|2021Cited by 211
CCL21-DC in situ vaccination in murine NSCLC overcomes resistance to immunotherapy and generates systemic tumor-specific immunityRamin Salehi‐Rad, Steven M. Dubinett, Bitta Kahangi et al.|Journal for ImmunoTherapy of Cancer|2023Cited by 30
Clofazimine is a broad-spectrum coronavirus inhibitor that antagonizes SARS-CoV-2 replication in primary human cell culture and hamstersShuofeng Yuan, Kwok‐Yung Yuen, Xin Yin et al.|Research Square|2020Cited by 22
Interferon Epsilon Loss Is Elusive 9p21 Link to Immune-Cold Tumors, Resistant to Immune Checkpoint Therapy, and Endogenous CXCL9/10 InductionXin Zhao, Scott M. Lippman, Bin Liu et al.|Journal of Thoracic Oncology|2024Cited by 12
Development of high affinity monobodies recognizing SARS-CoV-2 antigenYushen Du, Ren Sun|Research Square (Research Square)|2020Cited by 9